摘要
作者曾报告在鹤壁市郊用复合核黄素阻断治疗食管癌前增生，初试断续12年，累积癌变率为5．8％（8／137），而相应时间的自然癌变率为14．9％（79／530）。又重复试验3年，总体及重增癌抑制率为57．1％及63．3％（P＜0．05）。现报告停疗2年复查结果：总体及重增癌抑制率分别降至33．3％及50．7％（P＞0．2）。各级人群分别统计结果发现：复合核黄素癌阻断作用因增生级别而异，在治疗期SSI的癌抑制率为68．4％（P＜0．05），停疗后仍有54．7％（X2＝3．82），对其他各级作用均不明显（P＞0．2）。从而提示复合核黄素主要抑制早期重增癌变，且必需长期坚持服用，方有使发病及死亡率下降可能。
Compound riboflavin(CoB2)has been used to treat patient suffering from esophageal dysplasia (ED). In the first trial performed during 1 978-89, the accumulative cancer incidence rate was 5. 8 % (8/137), while it was 14. 9 54 (79/530) In the eontrol cohort in I.lnxlan. on the basis of the first trial,the study was repeated with an enrollment of 1006 subjects in Hebi from 1988-91. As a result, an inhibltory rate (CIR ) of 57. 1 % (P< 0. 05 )was achieved. At the end of 2 years after cessation of the drug,the total CIR was decreased to 33. 3%. It indicated that there was no remote effect when the CoB2 was discontinued. However, in terms of cell grading, it was revealed that the benefit of CoB2 varied with different cellular grades. During the treatment, the CIR of SSI was 68. 4 % (P<0. 05 ) and after cessation it was 54. 7% (X2= 3. 82). It is suggested that CoB2 mainly inhibits canceration in the early ED(SSI) and should be continued for a longer time.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1997年第5期331-334,共4页
Chinese Journal of Clinical Oncology
关键词
食管肿瘤
癌前增生
复合核黄素
药物疗法
Esophageal cytology Esophageal dysplasia Compund riboflavin Nutritional intervention
